secwatch.observer — SEC 8-K summary
======================================

Issuer:     Atara Biotherapeutics, Inc. (ATRA)
CIK:        0001604464
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001193125-25-113811
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on Atara's EBVALLO program; Type A meeting granted
--------------------------------------------------------------------------

- FDA lifted clinical hold on EBVALLO (tabelecleucel) IND applications, allowing resumption of Phase 3 ALLELE and Phase 2 label-expansion studies.
- FDA granted a Type A meeting to discuss path forward for BLA resubmission after January 2025 CRL citing GMP issues at third-party facility.
- Strategic option evaluation temporarily paused pending FDA clarity on BLA resubmission timing.
- Clinical hold directly linked to GMP compliance issues identified during pre-license inspection; resolved with supplemental finished drug product data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/0001193125-25-113811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1604464/000119312525113811/d905721d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-113811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer